A new study has shown that patients with coexisting type 2 diabetes mellitus and prostate cancer had significantly improved overall survival if they received thiazolidinediones (Kaplan–Meier log-rank, P = 0.005) or metformin (P = 0.035) but not if they received insulin or an insulin secretagog for their diabetes. Antidiabetic therapy in these patients could, therefore, be tailored to improve their survival.
ORIGINAL RESEARCH PAPER
He, X.-X. et al. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann. Oncol. 22, 2640–2645 (2011)
Rights and permissions
About this article
Cite this article
Choice of treatment for coexisting diabetes affects survival. Nat Rev Urol 9, 5 (2012). https://doi.org/10.1038/nrurol.2011.215
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2011.215